A Synergistically Enhanced T1–T2 Dual‐Modal Contrast Agent

Zhou, Zijian; Huang, Dengtong; Bao, Jianfeng; Chen, Qiaoli; Liu, Gang; Chen, Zhong; Chen, Xiaoyuan; Gao, Jinhao

doi:10.1002/adma.201203169

Cited by 278 publications

(261 citation statements)

References 43 publications

Supporting

Mentioning

255

Contrasting

Unclassified

Order By: Relevance

“…When the hepatic carcinoma reached 3-5 mm in diameter, we intravenously injected Octapod-30 and Spherical-16 into the nude mice (2 mg Fe per kg) and scanned the animals at a 7T microMRI scanner. As hepatic tumours contain much less active Kupffer cells and macrophages 36 , they do not accumulate iron oxide nanoparticles as efficiently as normal liver tissues do 40,41 . Thus, the hepatic tumours would show pseudo-positive contrast as compared with normal liver tissues.…”

Section: Synthesis and Characterizationmentioning

confidence: 99%

“…As the as-prepared nanoparticles were hydrophobic and unsuitable for biomedical applications, we transferred the nanoparticles to aqueous media using the conjugates of dendritic molecules and 1-hexadecylamine (denoted as HDA-G 2 ) by a hydrophobic-hydrophobic interaction 36 . The encapsulated nanoparticles showed excellent colloidal stability in aqueous solution.…”

Section: Synthesis and Characterizationmentioning

confidence: 99%

See 1 more Smart Citation

Octapod iron oxide nanoparticles as high-performance T2 contrast agents for magnetic resonance imaging

et al. 2013

Self Cite

View full text Add to dashboard Cite

Spherical superparamagnetic iron oxide nanoparticles have been developed as T 2 -negative contrast agents for magnetic resonance imaging in clinical use because of their biocompatibility and ease of synthesis; however, they exhibit relatively low transverse relaxivity. Here we report a new strategy to achieve high transverse relaxivity by controlling the morphology of iron oxide nanoparticles. We successfully fabricate size-controllable octapod iron oxide nanoparticles by introducing chloride anions. The octapod iron oxide nanoparticles (edge length of 30 nm) exhibit an ultrahigh transverse relaxivity value (679.3±30 mM À 1 s À 1 ), indicating that these octapod iron oxide nanoparticles are much more effective T 2 contrast agents for in vivo imaging and small tumour detection in comparison with conventional iron oxide nanoparticles, which holds great promise for highly sensitive, early stage and accurate detection of cancer in the clinic.

show abstract

Section: Synthesis and Characterizationmentioning

confidence: 99%

Section: Synthesis and Characterizationmentioning

confidence: 99%

Octapod iron oxide nanoparticles as high-performance T2 contrast agents for magnetic resonance imaging

et al. 2013

Self Cite

View full text Add to dashboard Cite

show abstract

“…[1][2][3] The modalities of MI technologies are currently used in optical imaging, 4 ultrasound, 5 magnetic resonance imaging, 6 computed tomography (CT), 7 and positron-emission tomography. 8 As one of the most commonly used MI technologies, CT offers more spatial anatomic details with high resolution than other imaging modalities.…”

Section: Introductionmentioning

confidence: 99%

Engineering iodine-doped carbon dots as dual-modal probes for fluorescence and X-ray CT imaging

Zhang¹,

Ju²,

Zhang³

et al. 2015

IJN

View full text Add to dashboard Cite

X-ray computed tomography (CT) is the most commonly used imaging technique for noninvasive diagnosis of disease. In order to improve tissue specificity and prevent adverse effects, we report the design and synthesis of iodine-doped carbon dots (I-doped CDs) as efficient CT contrast agents and fluorescence probe by a facile bottom-up hydrothermal carbonization process. The as-prepared I-doped CDs are monodispersed spherical nanoparticles (a diameter of ~2.7 nm) with favorable dispersibility and colloidal stability in water. The aqueous solution of I-doped CDs showed wavelength-dependent excitation and stable photoluminescence similar to traditional carbon quantum dots. Importantly, I-doped CDs displayed superior X-ray attenuation properties in vitro and excellent biocompatibility. After intravenous injection, I-doped CDs were distributed throughout the body and excreted by renal clearance. These findings validated that I-doped CDs with high X-ray attenuation potency and favorable photoluminescence show great promise for biomedical research and disease diagnosis.

show abstract

“…One issue is that the magnetic properties of iron oxide nanoparticles (e.g., magnetic susceptibility) still require modification with higher sensitivity for cancer detection by MRI 85, 86. The development of T1–T2 dual‐modal contrast agents will potentially solve this drawback, as it can simultaneously provide T1‐weighted imaging with a high tissue resolution and T2‐weighted imaging with a high feasibility, for tumor detection 70, 87. Besides, the therapeutic agents are usually loaded on the surface of iron oxide nanoparticles, which is difficult to carry and deliver sufficient dose of drugs to MDR cancers 88.…”

Section: Inorganic Nanocarriers Overcoming Drug Resistance For Cancermentioning

confidence: 99%

Inorganic Nanocarriers Overcoming Multidrug Resistance for Cancer Theranostics

et al. 2016

Self Cite

View full text Add to dashboard Cite

Cancer multidrug resistance (MDR) could lead to therapeutic failure of chemotherapy and radiotherapy, and has become one of the main obstacles to successful cancer treatment. Some advanced drug delivery platforms, such as inorganic nanocarriers, demonstrate a high potential for cancer theranostic to overcome the cancer‐specific limitation of conventional low‐molecular‐weight anticancer agents and imaging probes. Specifically, it could achieve synergetic therapeutic effects, demonstrating stronger killing effects to MDR cancer cells by combining the inorganic nanocarriers with other treatment manners, such as RNA interference and thermal therapy. Moreover, the inorganic nanocarriers could provide imaging functions to help monitor treatment responses, e.g., drug resistance and therapeutic effects, as well as analyze the mechanism of MDR by molecular imaging modalities. In this review, the mechanisms involved in cancer MDR and recent advances of applying inorganic nanocarriers for MDR cancer imaging and therapy are summarized. The inorganic nanocarriers may circumvent cancer MDR for effective therapy and provide a way to track the therapeutic processes for real‐time molecular imaging, demonstrating high performance in studying the interaction of nanocarriers and MDR cancer cells/tissues in laboratory study and further shedding light on elaborate design of nanocarriers that could overcome MDR for clinical translation.

show abstract

A Synergistically Enhanced T₁–T₂ Dual‐Modal Contrast Agent

Cited by 278 publications

References 43 publications

Octapod iron oxide nanoparticles as high-performance T2 contrast agents for magnetic resonance imaging

Octapod iron oxide nanoparticles as high-performance T2 contrast agents for magnetic resonance imaging

Engineering iodine-doped carbon dots as dual-modal probes for fluorescence and X-ray CT imaging

Inorganic Nanocarriers Overcoming Multidrug Resistance for Cancer Theranostics

Contact Info

Product

Resources

About